Vascoten

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vascoten

What is Vascoten? Identity and Pharmacological Class

Property Description
Active ingredient Atenolol
Form Oral tablet
Pharmacological class Beta-blocker (eta-adrenoceptor antagonist)
General purpose Supports heart function and blood pressure regulation
Origin Synthetic compound

Vascoten is a synthetic, single-ingredient oral medication whose active chemical substance is Atenolol, primarily classified as a Beta-blocker (eta-adrenoceptor antagonist) and used as an antihypertensive agent. This means the medicine is designed to interfere with certain chemical signals in the body that regulate heart function and blood pressure. Vascoten's specific action is defined by its chemical entity, Atenolol, which is a eta1-selective antagonist—often described as a cardio-selective eta-blocker—giving it a preference for receptors predominantly located in the heart muscle. The product's fundamental identity is rooted in this highly defined mechanism, which is clinically recognized for its systemic effects on blood pressure and heart rate.

Composition, Origin, and Form

The medicinal entity Vascoten is supplied as an oral tablet for oral administration, and it is strictly defined as a monotherapy containing only Atenolol as the active ingredient. Atenolol is a synthetic compound derived as a phenoxypropanolamine derivative. The product's consistent presentation as a solid, oral tablet distinguishes its physical form from liquid or injectable cardiovascular preparations. Its mechanism involves selective antagonism, blocking the signals that cause the heart rate to speed up and the muscle to contract too forcefully. This regulatory action results in both a slowing of the heart rate and a reduction in the physical intensity of each beat. The overall purpose of Vascoten is to promote more efficient cardiovascular function and reduce the heart's oxygen demand, supporting a steadier circulatory system.

Regulatory References

  1. Atenolol - StatPearls - NCBI Bookshelf

What side effects are possible with Vascoten?

Possible Side Effects and Safety Information

The official safety profile for Vascoten (Atenolol) details adverse reactions categorized by frequency and the body system affected, consistent with regulatory standards (e.g., EMA/FDA). These classifications distinguish between common and clinically significant effects.


Frequency-Classified Adverse Reactions

Adverse effects are categorized based on their documented occurrence rates:

  • Common (ge 1/100): May include bradycardia (slow heart rate), fatigue, cold extremities, and mild gastrointestinal disturbances like diarrhea.
  • Rare (ge 1/10,000): Documented effects include psychiatric disorders (e.g., mood changes, hallucinations), dry eyes, and certain blood changes, such as thrombocytopenia.

Serious Adverse Reactions and Safety Constraints

Regulatory documents highlight the potential for certain severe reactions and strict limitations on use.

Safety Domain Regulatory Statement
Serious Reactions Potential for aggravation of heart failure, severe bradycardia, and third-degree heart block are documented in regulatory sources.
Safety Restrictions The medicine is contraindicated in conditions like cardiogenic shock, severe bradycardia, and uncontrolled heart failure.
Withdrawal Pattern The label notes the critical importance of avoiding abrupt cessation of treatment, as this may exacerbate conditions, particularly for patients with coronary artery disease.

Population-Specific Considerations

Official safety information states that dose selection requires caution in older adults (geriatrics) and mandatory dose reduction for patients with renal impairment due to the drug’s primary route of elimination.

Overdose and Emergency Response

Overdose and when to seek help

The official overdose profile for Vascoten (Atenolol) is defined by an exaggeration of its intended pharmacological effects, primarily impacting the cardiovascular system. Documented clinical manifestations of overdose include severe bradycardia (abnormally slow heart rate), significant hypotension (low blood pressure), and sinus pause (an interruption of heart rhythm). Other documented systemic effects are lethargy, respiratory difficulties such as bronchospasm, and metabolic changes like hypoglycemia (low blood sugar).

Severe outcomes that may occur include profound hypotension, congestive heart failure, and disorder of respiratory drive. The official regulatory guidance mandates that individuals seek immediate medical attention or contact emergency services right away if an overdose is suspected or confirmed.

Management procedures described in regulatory documents are symptomatic and supportive. These include procedures for the removal of unabsorbed drug, such as gastric lavage or administration of activated charcoal. Furthermore, Atenolol is noted to be removable by hemodialysis from the general circulation. Special consideration is noted for patients with impaired renal function due to the increased risk of drug accumulation.

Therapeutic Uses of Vascoten

What Vascoten Treats: Main Uses and Benefits

Vascoten, containing Atenolol, is commonly used to manage a range of conditions primarily focused on supporting heart function and systemic blood pressure. The medication is relevant for easing symptoms related to heart-related issues and is applied across clinical settings that involve heightened systemic burden, providing symptomatic support that helps achieve greater daily stability. The main therapeutic areas of use generally include managing chronic hypertension, easing symptoms of Angina Pectoris, addressing certain types of tachycardia, and providing long-term support following an Acute Myocardial Infarction.


Key Therapeutic Focus

The medication helps address symptom clusters that may become intense or disruptive, especially those linked to organ-specific functional stress on the heart. For patients, Vascoten contributes to improved comfort during symptomatic periods and may assist with managing the overall symptom load associated with chronic cardiovascular issues. This use assists with maintaining functional stability and supports the patient during difficult episodes by easing distress.

Quick Fact: Relief for Symptoms of Angina
Vascoten is commonly used to help with symptoms associated with acute or episodic changes linked to Angina Pectoris, helping to ease the physical discomfort that creates noticeable physiological strain.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Vascoten?

The official eligibility for Vascoten (Atenolol) is strictly determined by specific patient conditions and demographic factors, as defined in government regulatory documents.


Absolute Contraindications

Vascoten is contraindicated and must not be used in populations presenting with severe, existing cardiac conditions. This prohibition includes patients with second- or third-degree heart block, cardiogenic shock, sinus bradycardia, or uncompensated heart failure. Use is also prohibited in cases of metabolic acidosis and severe peripheral arterial circulatory disturbances. Patients with known hypersensitivity to the drug's components are also non-eligible.


Age and Physiological Restrictions

  • Pediatric Use: The medication is not recommended for children and adolescents (under 18 years) because its safety and efficacy have not been formally established.
  • Renal Function: Use is restricted in patients with severe renal impairment and necessitates a mandatory adjustment of the dose based on reduced creatinine clearance.
  • Pregnancy/Lactation: Use during pregnancy is restricted and not generally recommended due to documented risks of fetal harm, including growth restriction. Caution is officially advised during lactation as the drug is excreted into human milk.

Conditional Eligibility

Patients with diabetes mellitus or bronchospastic disease require conditional use and close monitoring, as the drug may mask hypoglycemia symptoms or potentially aggravate respiratory conditions.

What should I know about interactions with other medicines?

Vascoten Interactions with other medicines and products

This section outlines official interaction information for Vascoten (Atenolol) as described in regulatory documents.

Documented Pharmacodynamic Interactions

Interactions that affect the heart's rate or function are commonly noted:

  • Calcium Channel Blockers (e.g., Verapamil, Diltiazem) and Antiarrhythmic Drugs (e.g., Amiodarone) may cause an additive effect, increasing the risk of marked bradycardia (slow heart rate) and atrioventricular (AV) block.
  • Co-administration with Cardiac Glycosides (e.g., Digoxin) also increases the risk of marked bradycardia.
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs), such as Aspirin, may lessen the intended blood-pressure-lowering effect due to pharmacodynamic antagonism.

Administration and Exposure Constraints

Constraint Type Interacting Substance Regulatory Requirement
Timing Rule Aluminum Hydroxide (Antacids) Must be administered at least 2 hours apart to prevent reduced absorption of Vascoten.
Procedural Rule Clonidine Vascoten must be discontinued first and the withdrawal of Clonidine completed several days later to avoid potential severe rebound hypertension.

Population-Specific Interaction Notes

Since Vascoten is primarily eliminated through the kidneys, Impaired Renal Function causes significant drug accumulation when creatinine clearance is low. This may increase the likelihood or severity of interactions. Older patients also frequently exhibit reduced glomerular filtration, influencing drug clearance and elimination half-life.

Mechanism of Action

Vascoten's action centers entirely on the beta1-Adrenergic Receptor (beta1-AR), initiating a two-pronged physiological cascade that modulates sympathetic signaling. Its high specificity for beta1-AR over beta2-AR defines its core mechanistic profile; this preference results in reduced beta2-adrenergic receptor engagement in non-cardiac tissues. The core mechanism involves competitive antagonism at the beta1-AR site in the myocardium, which blocks the stimulatory effects of endogenous hormones like Norepinephrine and Epinephrine. This suppression of the sympathetic signal reduces the intracellular cascade responsible for exciting cardiac cells, resulting in a negative chronotropic effect and a negative inotropic effect. Vascoten also engages the beta1-ARs found in the juxtaglomerular apparatus (JGA) of the kidney. The antagonism here suppresses the release of the key enzyme Renin, which is responsible for initiating the Renin-Angiotensin-Aldosterone System (RAAS). Modulating this hormonal system contributes to a subsequent reduction in systemic vascular tone, which integrates with the direct cardiac effects to determine the overall physiological consequence.

Dosage and Administration Information

The administration of Vascoten (Atenolol) is governed by its approved forms and standardized schedules, beginning with the method of delivery. The medicine is primarily administered via the oral route as a tablet for chronic long-term management; however, an Intravenous (IV) form is specifically reserved for the initial, acute intervention phase following a myocardial infarction within a monitored hospital setting.

For chronic uses like hypertension, the maintenance regimen typically involves taking 50 mg to 100 mg once daily. For angina pectoris, a dose of 100 mg once daily is common, although some regimens allow for a total of up to 200 mg per day, which may be taken as divided doses. The tablets may be taken with or without food, and if a dose is missed, the user is instructed to skip it if it is near the time of the next dose, and never to take a double dose.

A critical procedural rule is the gradual withdrawal requirement; Vascoten treatment must not be abruptly stopped but rather tapered over a period of one to two weeks to prevent potential exacerbation of underlying conditions. Mandatory dose adjustments apply to specific populations: patients with renal impairment require reductions based on their creatinine clearance. For instance, individuals with creatinine clearance between 15 and 35 mL/ min are typically limited to a maximum of 50 mg daily. The intravenous phase of treatment and dosing during hemodialysis both require hospital supervision.

Recent Clinical Evidence

Vascoten: Recent Clinical Evidence

Phase 3 Clinical Trial Data

Clinical studies have evaluated whether the use of Vascoten is associated with improvements in functional capacity and quality of life across the studied patient population. Research has explored its potential role in the management of symptoms. Studies documenting its absorption examined the influence of food intake on drug concentration.

These studies observed changes in patient-reported outcomes across key scales. The initial studies tracked changes in patient status during the first week of administration.


Mechanism of Action and Efficacy

Research has investigated whether the use of the drug is associated with changes in inflammation biomarkers in laboratory models and human trials.

Studies in patients with moderate-to-severe symptoms have been conducted. The primary focus of those studies was the duration of remission following treatment cessation.


Long-term and Combination Therapy

Sustained Efficacy Studies

Long-term follow-up studies extending over one year have tracked patient status to understand the durability of the observed effects. Research results remain limited on whether the observed improvements were maintained beyond the follow-up period.

Combination Treatment Analysis

Combination therapy research has assessed the long-term changes in the frequency of flare-ups when the drug was administered alongside established medications. Comparative trials have been conducted to evaluate changes in pain scores relative to other treatments.


Safety Profile in Specific Populations

Studies in populations including those with pre-existing kidney conditions monitored for adverse events and changes in renal function markers. Specific research has examined the drug's profile when used as an initial treatment option.

Key Studies & References

  1. Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic nHCM (ACACIA-HCM) - ClinicalTrials.gov

Frequently Asked Questions (FAQ)

Common questions about Vascoten (FAQ)


Q: Can Vascoten be taken with common pain relievers like ibuprofen or acetaminophen?

Official information notes that certain Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which includes ibuprofen, may reduce the intended blood-pressure-lowering effect of Vascoten. While no specific interaction is typically listed for acetaminophen in official drug labels, it is important to review all medications, including over-the-counter pain relievers, with a healthcare provider.


Q: Does Vascoten need to be taken with food, or can it be taken on an empty stomach?

According to the official product information, Vascoten tablets may be taken either with or without food. To promote consistent drug levels, regulatory guidance recommends administering the tablet in a consistent manner relative to food.


Q: How long does the effect of one dose of Vascoten typically last?

Official documents indicate that the beneficial effects of Vascoten are usually measurable for at least 24 hours after taking a single oral dose, consistent with its use as a once-daily medicine. The body's absorption of the drug often results in the highest concentrations within two to four hours after taking a dose.


Q: Can Vascoten cause problems with liver or kidney function?

Because Vascoten is primarily eliminated by the kidneys, official guidelines require checking renal function status, as patients with impaired kidney function may require different dosing regimens. Rarely documented adverse effects include transient elevations in liver enzymes, which may indicate changes in liver function.


Q: What is the main difference between Vascoten and other similar drugs for the same condition?

Vascoten belongs to the beta-blocker class and is officially described as a beta1-selective antagonist. This preference for beta1 receptors is officially described as cardio-selective, meaning its action is focused on receptors predominantly found in the heart, rather than those found elsewhere.


Q: Is Vascoten the same as [Name of a common similar drug]?

The active ingredient in Vascoten is Atenolol. While other drugs may belong to the same pharmacological class (beta-blockers) and may treat similar conditions, they contain different active chemical substances. The specific name and composition of each medicine define its unique identity.


Q: Does Vascoten contain a steroid?

No. The active ingredient in Vascoten is Atenolol, which is a synthetic compound classified as a beta-blocker. Official descriptions of its chemical identity confirm that it is not a steroid-containing compound.


Q: Is Vascoten safe to use long-term?

Vascoten is indicated and prescribed for the chronic, long-term management of conditions such as hypertension and angina pectoris. Official drug documents provide specific dosing information for continuous, long-term use.


Q: How quickly does Vascoten start to work?

According to the official drug label, the initial measurable effects of the drug in the body are typically noted within one hour after taking an oral dose. Full clinical effects for conditions like high blood pressure may take longer to develop.


Q: Can Vascoten cause weight gain?

Weight gain is noted in some general medical literature as a possible side effect of certain older beta-blockers, including Atenolol. Regulatory documents mention that weight gain should be monitored, as it may be a physical sign of fluid retention related to heart failure deterioration.


Q: Does Vascoten interact with caffeine or energy drinks?

Official drug labels do not list a direct, specific interaction between Vascoten and caffeine alone. However, official information suggests caution when Vascoten is combined with substances classified as Central Nervous System (CNS) stimulants, due to the potential for opposing effects.


Q: Are there any known foods or supplements that interact with Vascoten?

Official drug labels mention that the absorption of Vascoten may be decreased if taken with Aluminum Hydroxide (an antacid), requiring a separation of at least two hours between the medicines. There is also information advising that large amounts of orange juice should be avoided as this may potentially decrease the drug's effectiveness.


Q: Does Vascoten affect sleep quality?

Yes, according to official safety information, Vascoten is associated with certain side effects that can affect sleep. These documented effects include sleep disturbances, nightmares, and insomnia.


Q: Is Vascoten habit-forming or addictive?

Vascoten (Atenolol) is not classified as a controlled substance by regulatory agencies and is not considered habit-forming. Official warnings instead highlight the need for a gradual reduction of the dose when stopping the medication, to avoid a physiological rebound effect.


Q: What are the official warnings about Vascoten and alcohol?

Official warnings note that consuming alcohol may have an additive effect with Vascoten in lowering blood pressure. Official warnings indicate that this combination may be associated with an increased occurrence of symptoms like dizziness, lightheadedness, or fainting.


Q: Are there any specific laboratory tests required before starting Vascoten?

While the drug label does not mandate specific routine tests, official guidance indicates that a patient's renal function status, determined by measuring creatinine clearance levels, is necessary to confirm appropriate dosage selection.


Q: What are the official sources saying about Vascoten's effectiveness?

Official regulatory documents indicate Vascoten is an effective antihypertensive agent that provides a 24-hour reduction of blood pressure. It is officially indicated for the treatment of hypertension, angina pectoris, and for reducing cardiovascular mortality following an acute myocardial infarction.


Q: Is Vascoten safe for people with asthma or other respiratory issues?

Official documents state that Vascoten should be used with caution in patients with bronchospastic disease, such as asthma. Because the drug may potentially aggravate these respiratory conditions, official documents indicate that use in this population requires a conditional review and careful observation.


Q: What happens if Vascoten is taken with a multivitamin?

Official information advises that taking Vascoten with a multivitamin that contains minerals may decrease the absorption of Vascoten. To manage this potential decrease in absorption, official guidance suggests separating the administration times by at least two hours.


Q: Does Vascoten interact with herbal supplements like St. John's Wort?

The drug label may not always explicitly list specific herbal supplements. However, official pharmacokinetic data suggest that the drug's metabolism could be altered by certain herbal substances, which could potentially lead to increased or decreased effects.


Q: Can Vascoten cause changes in appetite?

Changes in appetite are documented as a less common adverse effect.


Q: Can Vascoten affect a person's ability to drive or operate machinery?

Official patient information advises caution when driving or operating hazardous machinery. Because Vascoten can cause side effects like dizziness, drowsiness, or lightheadedness, official patient information advises limiting these activities until the individual is aware of how the medication affects them.


Q: How long do most people take Vascoten for?

Vascoten is officially indicated for the chronic, long-term management of high blood pressure and other conditions. The duration of treatment is typically indefinite, meaning use continues as long as the condition requires and the medicine is tolerated.


Q: Do studies show Vascoten is less effective over time?

Vascoten is officially cited as providing a sustained, 24-hour reduction of blood pressure and is prescribed for long-term use. The official documents do not suggest a loss of its primary antihypertensive effect over time for the approved indications.


Q: Is Vascoten safe for people with a history of heart problems?

Official warnings state that Vascoten is contraindicated (must not be used) in patients with certain severe, current heart conditions (e.g., cardiogenic shock). Official warnings highlight the need for caution in this population, noting that abrupt discontinuation may cause the underlying condition to worsen.

How should Vascoten be stored and disposed of?

How to Store and Dispose of Vascoten?

Storage

To maintain its effectiveness, store Vascoten tablets in their original container at room temperature, typically between 68 F to 77 F (20 C to 25 C). Keep the medication away from excessive heat and moisture, which means avoiding locations like a bathroom medicine cabinet. Always ensure Vascoten is stored securely out of the sight and reach of children and pets to prevent accidental ingestion.

Disposal

Dispose of unused or expired Vascoten promptly and safely. The best option is to utilize a drug take-back program, which may be offered by local pharmacies or law enforcement during national drug take-back events.

If a take-back program is unavailable, you can dispose of the medication in your household trash by taking the following steps:

  1. Remove the tablets from their original container and mix them with an undesirable substance such as used coffee grounds, dirt, or cat litter (do not crush the tablets).
  2. Place the mixture into a sealed bag or container to prevent leakage.
  3. Scratch out all personal identifying information on the prescription label of the empty container before discarding it.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vascoten found in:

A-Z Index: